S. Létard

Oncogenic tyrosine kinase of malignant hemopathy targets the centrosome.

Daniel Birnbaum, D. Birnbaum, B. Delaval, 2005, Cancer research.

In aggressive forms of mastocytosis, TET2 loss cooperates with c-KITD816V to transform mast cells.

O. Bernard, S. Létard, P. Dubreuil, 2012, Blood.

Comparison of effects of midostaurin, crenolanib, quizartinib, gilteritinib, sorafenib and BLU‐285 on oncogenic mutants of KIT, CBL and FLT3 in haematological malignancies

N. Gray, Jinhua Wang, J. Griffin, 2019, British journal of haematology.

Suppressor of Cytokine Signaling 6 Associates with KIT and Regulates KIT Receptor Signaling*

R. Frank, S. Létard, P. Dubreuil, 2004, Journal of Biological Chemistry.

Signal transduction by several KIT juxtamembrane domain mutations

R. Rottapel, S. Létard, P. Dubreuil, 2003, Oncogene.

Mastocytosis in mice expressing human Kit receptor with the activating Asp816Val mutation

G. Delsol, R. Liblau, S. Létard, 2005, The Journal of experimental medicine.

Dual Role of the Tyrosine Kinase Syk in Regulation of Toll-Like Receptor Signaling in Plasmacytoid Dendritic Cells

D. Olive, J. Nunès, S. Létard, 2016, PloS one.

Identification of new aminoacid amides containing the imidazo[2,1-b]benzothiazol-2-ylphenyl moiety as inhibitors of tumorigenesis by oncogenic Met signaling.

A. Furlan, C. Tintori, M. Botta, 2012, European journal of medicinal chemistry.